AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
OTGLF CD Projekt SA
HRL Hormel Foods Corp
IPOF Social Capital Hedosophia Holdings Corp VI
NIO NIO Inc
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
HSIC Henry Schein Inc
Go

Health Care : Pharmaceuticals | Large Cap Growth
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$54.40
Day's Change
0.39 (0.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
54.60
Day's Low
54.19
Volume
(Average)

Today's volume of 7,952,243 shares is on pace to be in-line with AZN's 10-day average volume of 12,418,274 shares.

7,952,243
Latest Earnings Beat Consensus (Q3 ending 09/2020)Next Earnings Announcement
Q3
Announced November 5, 2020
$0.47Q3 Consensus
of 1 analysts
$0.44Difference from
consensus
6.38%
Q4 Earnings
will announce
(Unconfirmed) February 11, 2021

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

AZN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.